However, combining the angiomotin DNA vaccine with another targeting extracellular and transmembrane domains of human Her-2 resulted in dramatic tumor growth impairment in the transgenic model, demonstrating increased tumor-free survival. The gene discussed is ERBB2; the disease is neoplasm.